Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2001 Mar;77(905):166–171. doi: 10.1136/pmj.77.905.166

Thrombolysis in acute ischaemic stroke

A Pereira 1, P Martin 1, E Warburton 1
PMCID: PMC1741956  PMID: 11222823

Full Text

The Full Text of this article is available as a PDF (130.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albers G. W., Bates V. E., Clark W. M., Bell R., Verro P., Hamilton S. A. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000 Mar 1;283(9):1145–1150. doi: 10.1001/jama.283.9.1145. [DOI] [PubMed] [Google Scholar]
  2. Albers G. W. Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection. Stroke. 1999 Oct;30(10):2230–2237. doi: 10.1161/01.str.30.10.2230. [DOI] [PubMed] [Google Scholar]
  3. Back T., Hoehn-Berlage M., Kohno K., Hossmann K. A. Diffusion nuclear magnetic resonance imaging in experimental stroke. Correlation with cerebral metabolites. Stroke. 1994 Feb;25(2):494–500. doi: 10.1161/01.str.25.2.494. [DOI] [PubMed] [Google Scholar]
  4. Baird A. E., Benfield A., Schlaug G., Siewert B., Lövblad K. O., Edelman R. R., Warach S. Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol. 1997 May;41(5):581–589. doi: 10.1002/ana.410410506. [DOI] [PubMed] [Google Scholar]
  5. Baird A. E., Warach S. Magnetic resonance imaging of acute stroke. J Cereb Blood Flow Metab. 1998 Jun;18(6):583–609. doi: 10.1097/00004647-199806000-00001. [DOI] [PubMed] [Google Scholar]
  6. Bamford J., Sandercock P., Dennis M., Burn J., Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991 Jun 22;337(8756):1521–1526. doi: 10.1016/0140-6736(91)93206-o. [DOI] [PubMed] [Google Scholar]
  7. Barber P. A., Darby D. G., Desmond P. M., Yang Q., Gerraty R. P., Jolley D., Donnan G. A., Tress B. M., Davis S. M. Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI. Neurology. 1998 Aug;51(2):418–426. doi: 10.1212/wnl.51.2.418. [DOI] [PubMed] [Google Scholar]
  8. Baron J. C., von Kummer R., del Zoppo G. J. Treatment of acute ischemic stroke. Challenging the concept of a rigid and universal time window. Stroke. 1995 Dec;26(12):2219–2221. doi: 10.1161/01.str.26.12.2219. [DOI] [PubMed] [Google Scholar]
  9. Brott T. G., Haley E. C., Jr, Levy D. E., Barsan W., Broderick J., Sheppard G. L., Spilker J., Kongable G. L., Massey S., Reed R. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992 May;23(5):632–640. doi: 10.1161/01.str.23.5.632. [DOI] [PubMed] [Google Scholar]
  10. Bryan R. N., Levy L. M., Whitlow W. D., Killian J. M., Preziosi T. J., Rosario J. A. Diagnosis of acute cerebral infarction: comparison of CT and MR imaging. AJNR Am J Neuroradiol. 1991 Jul-Aug;12(4):611–620. [PMC free article] [PubMed] [Google Scholar]
  11. Busza A. L., Allen K. L., King M. D., van Bruggen N., Williams S. R., Gadian D. G. Diffusion-weighted imaging studies of cerebral ischemia in gerbils. Potential relevance to energy failure. Stroke. 1992 Nov;23(11):1602–1612. doi: 10.1161/01.str.23.11.1602. [DOI] [PubMed] [Google Scholar]
  12. Caplan L. R., Mohr J. P., Kistler J. P., Koroshetz W. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis--not a panacea for ischemic stroke. N Engl J Med. 1997 Oct 30;337(18):1309–1313. doi: 10.1056/NEJM199710303371812. [DOI] [PubMed] [Google Scholar]
  13. Chiu D., Krieger D., Villar-Cordova C., Kasner S. E., Morgenstern L. B., Bratina P. L., Yatsu F. M., Grotta J. C. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke. 1998 Jan;29(1):18–22. doi: 10.1161/01.str.29.1.18. [DOI] [PubMed] [Google Scholar]
  14. Clark W. M., Wissman S., Albers G. W., Jhamandas J. H., Madden K. P., Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999 Dec 1;282(21):2019–2026. doi: 10.1001/jama.282.21.2019. [DOI] [PubMed] [Google Scholar]
  15. Del Zoppo G. J., Copeland B. R., Waltz T. A., Zyroff J., Plow E. F., Harker L. A. The beneficial effect of intracarotid urokinase on acute stroke in a baboon model. Stroke. 1986 Jul-Aug;17(4):638–643. doi: 10.1161/01.str.17.4.638. [DOI] [PubMed] [Google Scholar]
  16. Donnan G. A., Davis S. M., Chambers B. R., Gates P. C., Hankey G. J., McNeil J. J., Rosen D., Stewart-Wynne E. G., Tuck R. R. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA. 1996 Sep 25;276(12):961–966. [PubMed] [Google Scholar]
  17. Donnan G. A., Davis S. M., Chambers B. R., Gates P. C., Hankey G. J., McNeil J. J., Rosen D., Stewart-Wynne E. G., Tuck R. R. Trials of streptokinase in severe acute ischaemic stroke. Lancet. 1995 Mar 4;345(8949):578–579. [PubMed] [Google Scholar]
  18. Fiorelli M., Bastianello S., von Kummer R., del Zoppo G. J., Larrue V., Lesaffre E., Ringleb A. P., Lorenzano S., Manelfe C., Bozzao L. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke. 1999 Nov;30(11):2280–2284. doi: 10.1161/01.str.30.11.2280. [DOI] [PubMed] [Google Scholar]
  19. Fisher M., Prichard J. W., Warach S. New magnetic resonance techniques for acute ischemic stroke. JAMA. 1995 Sep 20;274(11):908–911. [PubMed] [Google Scholar]
  20. Grond M., Stenzel C., Schmülling S., Rudolf J., Neveling M., Lechleuthner A., Schneweis S., Heiss W. D. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke. 1998 Aug;29(8):1544–1549. doi: 10.1161/01.str.29.8.1544. [DOI] [PubMed] [Google Scholar]
  21. Hacke W., Kaste M., Fieschi C., Toni D., Lesaffre E., von Kummer R., Boysen G., Bluhmki E., Höxter G., Mahagne M. H. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) JAMA. 1995 Oct 4;274(13):1017–1025. [PubMed] [Google Scholar]
  22. Hacke W., Kaste M., Fieschi C., von Kummer R., Davalos A., Meier D., Larrue V., Bluhmki E., Davis S., Donnan G. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998 Oct 17;352(9136):1245–1251. doi: 10.1016/s0140-6736(98)08020-9. [DOI] [PubMed] [Google Scholar]
  23. Haley E. C., Jr, Levy D. E., Brott T. G., Sheppard G. L., Wong M. C., Kongable G. L., Torner J. C., Marler J. R. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke. 1992 May;23(5):641–645. doi: 10.1161/01.str.23.5.641. [DOI] [PubMed] [Google Scholar]
  24. Howe F. A., Maxwell R. J., Saunders D. E., Brown M. M., Griffiths J. R. Proton spectroscopy in vivo. Magn Reson Q. 1993 Mar;9(1):31–59. [PubMed] [Google Scholar]
  25. Katzan I. L., Furlan A. J., Lloyd L. E., Frank J. I., Harper D. L., Hinchey J. A., Hammel J. P., Qu A., Sila C. A. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA. 2000 Mar 1;283(9):1151–1158. doi: 10.1001/jama.283.9.1151. [DOI] [PubMed] [Google Scholar]
  26. Kwiatkowski T. G., Libman R. B., Frankel M., Tilley B. C., Morgenstern L. B., Lu M., Broderick J. P., Lewandowski C. A., Marler J. R., Levine S. R. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med. 1999 Jun 10;340(23):1781–1787. doi: 10.1056/NEJM199906103402302. [DOI] [PubMed] [Google Scholar]
  27. Lindgren A., Norrving B., Rudling O., Johansson B. B. Comparison of clinical and neuroradiological findings in first-ever stroke. A population-based study. Stroke. 1994 Jul;25(7):1371–1377. doi: 10.1161/01.str.25.7.1371. [DOI] [PubMed] [Google Scholar]
  28. Lyden P. D., Madden K. P., Clark W. M., Sasse K. C., Zivin J. A. Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]. Stroke. 1990 Nov;21(11):1589–1593. doi: 10.1161/01.str.21.11.1589. [DOI] [PubMed] [Google Scholar]
  29. Lyden P. D., Zivin J. A., Clark W. A., Madden K., Sasse K. C., Mazzarella V. A., Terry R. D., Press G. A. Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits. Neurology. 1989 May;39(5):703–708. doi: 10.1212/wnl.39.5.703. [DOI] [PubMed] [Google Scholar]
  30. Marchal G., Beaudouin V., Rioux P., de la Sayette V., Le Doze F., Viader F., Derlon J. M., Baron J. C. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke: a correlative PET-CT study with voxel-based data analysis. Stroke. 1996 Apr;27(4):599–606. doi: 10.1161/01.str.27.4.599. [DOI] [PubMed] [Google Scholar]
  31. Memezawa H., Smith M. L., Siesjö B. K. Penumbral tissues salvaged by reperfusion following middle cerebral artery occlusion in rats. Stroke. 1992 Apr;23(4):552–559. doi: 10.1161/01.str.23.4.552. [DOI] [PubMed] [Google Scholar]
  32. Mohr J. P., Biller J., Hilal S. K., Yuh W. T., Tatemichi T. K., Hedges S., Tali E., Nguyen H., Mun I., Adams H. P., Jr Magnetic resonance versus computed tomographic imaging in acute stroke. Stroke. 1995 May;26(5):807–812. doi: 10.1161/01.str.26.5.807. [DOI] [PubMed] [Google Scholar]
  33. Moseley M. E., Butts K., Yenari M. A., Marks M., de Crespigny A. Clinical aspects of DWI. NMR Biomed. 1995 Nov-Dec;8(7-8):387–396. doi: 10.1002/nbm.1940080712. [DOI] [PubMed] [Google Scholar]
  34. Papadopoulos S. M., Chandler W. F., Salamat M. S., Topol E. J., Sackellares J. C. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke. J Neurosurg. 1987 Sep;67(3):394–398. doi: 10.3171/jns.1987.67.3.0394. [DOI] [PubMed] [Google Scholar]
  35. Pereira A. C., Saunders D. E., Doyle V. L., Bland J. M., Howe F. A., Griffiths J. R., Brown M. M. Measurement of initial N-acetyl aspartate concentration by magnetic resonance spectroscopy and initial infarct volume by MRI predicts outcome in patients with middle cerebral artery territory infarction. Stroke. 1999 Aug;30(8):1577–1582. doi: 10.1161/01.str.30.8.1577. [DOI] [PubMed] [Google Scholar]
  36. Ringelstein E. B., Biniek R., Weiller C., Ammeling B., Nolte P. N., Thron A. Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology. 1992 Feb;42(2):289–298. doi: 10.1212/wnl.42.2.289. [DOI] [PubMed] [Google Scholar]
  37. SUSSMAN B. J., FITCH T. S. Thrombolysis with fibrinolysin in cerebral arterial occlusion. J Am Med Assoc. 1958 Aug 2;167(14):1705–1709. doi: 10.1001/jama.1958.02990310011002. [DOI] [PubMed] [Google Scholar]
  38. Saunders D. E., Clifton A. G., Brown M. M. Measurement of infarct size using MRI predicts prognosis in middle cerebral artery infarction. Stroke. 1995 Dec;26(12):2272–2276. doi: 10.1161/01.str.26.12.2272. [DOI] [PubMed] [Google Scholar]
  39. Trouillas P., Nighoghossian N., Derex L., Adeleine P., Honnorat J., Neuschwander P., Riche G., Getenet J. C., Li W., Froment J. C. Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: determination of etiological, topographic, and radiological outcome factors. Stroke. 1998 Dec;29(12):2529–2540. doi: 10.1161/01.str.29.12.2529. [DOI] [PubMed] [Google Scholar]
  40. Trouillas P., Nighoghossian N., Getenet J. C., Riche G., Neuschwander P., Froment J. C., Turjman F., Jin J. X., Malicier D., Fournier G. Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke. Correlations of outcome with clinical and radiological data. Stroke. 1996 May;27(5):882–890. doi: 10.1161/01.str.27.5.882. [DOI] [PubMed] [Google Scholar]
  41. Warach S., Dashe J. F., Edelman R. R. Clinical outcome in ischemic stroke predicted by early diffusion-weighted and perfusion magnetic resonance imaging: a preliminary analysis. J Cereb Blood Flow Metab. 1996 Jan;16(1):53–59. doi: 10.1097/00004647-199601000-00006. [DOI] [PubMed] [Google Scholar]
  42. Wardlaw J. M., Lewis S. C., Dennis M. S., Counsell C., McDowall M. Is visible infarction on computed tomography associated with an adverse prognosis in acute ischemic stroke? Stroke. 1998 Jul;29(7):1315–1319. doi: 10.1161/01.str.29.7.1315. [DOI] [PubMed] [Google Scholar]
  43. Wardlaw J. M., Warlow C. P., Counsell C. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet. 1997 Aug 30;350(9078):607–614. doi: 10.1016/s0140-6736(97)03022-5. [DOI] [PubMed] [Google Scholar]
  44. Wolfson S. K., Jr, Clark J., Greenberg J. H., Gur D., Yonas H., Brenner R. P., Cook E. E., Lordeon P. A. Xenon-enhanced computed tomography compared with [14C]iodoantipyrine for normal and low cerebral blood flow states in baboons. Stroke. 1990 May;21(5):751–757. doi: 10.1161/01.str.21.5.751. [DOI] [PubMed] [Google Scholar]
  45. Zivin J. A., Lyden P. D., DeGirolami U., Kochhar A., Mazzarella V., Hemenway C. C., Johnston P. Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke. Arch Neurol. 1988 Apr;45(4):387–391. doi: 10.1001/archneur.1988.00520280033012. [DOI] [PubMed] [Google Scholar]
  46. del Zoppo G. J., Poeck K., Pessin M. S., Wolpert S. M., Furlan A. J., Ferbert A., Alberts M. J., Zivin J. A., Wechsler L., Busse O. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992 Jul;32(1):78–86. doi: 10.1002/ana.410320113. [DOI] [PubMed] [Google Scholar]
  47. del Zoppo G. J., von Kummer R., Hamann G. F. Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry. 1998 Jul;65(1):1–9. doi: 10.1136/jnnp.65.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. van Everdingen K. J., van der Grond J., Kappelle L. J., Ramos L. M., Mali W. P. Diffusion-weighted magnetic resonance imaging in acute stroke. Stroke. 1998 Sep;29(9):1783–1790. doi: 10.1161/01.str.29.9.1783. [DOI] [PubMed] [Google Scholar]
  49. von Kummer R., Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke. 1992 May;23(5):646–652. doi: 10.1161/01.str.23.5.646. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES